![Peter Rossing MD, DMSc](https://res.cloudinary.com/els-assets/image/upload/c_fill_pad,f_auto,g_auto,h_150,q_auto,w_120/v1/practice-update/remote-media/contentimage/19001.jpg)
Peter Rossing MD, DMSc
Head of Complications Research, Chief Physician, Steno Diabetes Center, Copenhagen, Denmark
Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes.
Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.
He is coordinator of the EU FP7 project PRIORITY aiming to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy.
He has co-authored >350 papers and his h-index is 65. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry.
Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.
He is coordinator of the EU FP7 project PRIORITY aiming to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy.
He has co-authored >350 papers and his h-index is 65. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry.
Disclosures
Dr. Rossing reports the following relevant disclosures: grants from Novo Nordisk and Astra Zeneca, advisory boards in Astra Zeneca, Bayer, Boehringer, Eli Lilly, Mundi, Novo Nordisk, Sanofi, Astellas, Abbvie (all fees to institution. Shares in Novo Nordisk.Recent Contributions to PracticeUpdate:
- Association Between SGLT2 Inhibitor Use and a Reduced Risk for New-Onset Type 2 Diabetes in Adults With Prediabetes
- Reduced Myocardial Perfusion Reserve in T2D Is Associated With Diabetes Complications
- Dulaglutide and Renal Outcomes in Type 2 Diabetes
- The Familiality of Rapid Renal Decline in Diabetes
- Decreased Long-Term Mortality After Kidney Transplantation in Patients With Type 1 Diabetes